Imfinzi, tremelimumab combo boosts survival in lung cancer
The POSEIDON trial is the first Phase III study to demonstrate an overall survival benefit with tremelimumab
Read More
Tag: tremelimumab
Setback for AZ’ Imfinzi lung cancer combination
AstraZeneca’s Imfinzi has failed to show a significant benefit over standard of care (SoC) chemotherapy on overall survival in certain patients with lung cancer.
Read More
AZ lung cancer combo fails to hit targets
A combination of immunotherapy drugs being tested by AstraZeneca in the third-line setting in patients with lung cancer has failed to slow disease progression or extend survival.
Read More
AZ expands first-line cancer immunotherapy programme
AstraZeneca has expanded a late-stage trial currently assessing a potential new immuno-oncology (IO) therapy combination for the first-line treatment of non-small cell lung cancer (NSCLC), to include extra endpoints for both the combo and monotherapy.
Read More
- Vandria reports positive phase 1 data for Alzheimer’s drug candidate
- HSE approves new treatment for hidradenitis suppurativa and axial spondyloarthritis
- MSD to acquire Cidara after positive phase 2b trial results
- eXmoor Pharma and Royal Free London link to strengthen UK gene therapy
- Alzheimer’s prevention charity pioneers research on nutrition biomarkers to detect risk
